Global While great strides in gender diversity has been made within healthcare boardrooms and leadership teams globally, as well as more generally across the workplace and many other arenas in many countries, at times we are served a stark reminder that the fight for greater gender equality and women representation is…
Roundup Recent news from the cross-border deals and partnerships being struck by Chinese pharmacos, including I-Mab’s USD 2 billion immuno-oncology collaboration with AbbVie, Jiangsu Hengrui’s latest deal with US biotech Dyadic, and Fosun Pharma’s role in the Pfizer/BioNTech COVID-19 vaccine. AbbVie and Chinese biotech I-Mab Enter Into Global Strategic Partnership…
China The only company in our Summer 2020 edition of InFocus: 5 Biotechs to Watch in China to be helmed by a non-founding CEO, I-Mab Biopharma has advanced since its establishment in 2017 at a pace that would seem to outpace the fast-moving China biotech industry. [Post-merger], I-Mab became an…
China 2020 will certainly go down in history as a watershed year for the global community, as a new strain of coronavirus – later named SARS-CoV-19 – originating from the city of Wuhan in China circulated around the world in just months, wreaking havoc on economies and disrupting the lives of…
China Dr Joan Shen, CEO of I-Mab Biopharma, shares her impressive career journey across companies like Pfizer, Janssen and Jiangsu Hengrui, before joining I-Mab, as well as introducing what I-Mab 2.0 might look like for the NASDAQ-listed biotech, their clinical pipeline and her leadership philosophy. Fundamentally, we need to keep…
China Alphamab Oncology and I-Mab Biopharma, two of China’s fastest-growing biotech firms, both bolstered by recent successful IPOs, are increasingly adapting their portfolio strategies to launch products on the large but challenging domestic Chinese market. I-Mab: Observing Competitors and Staying Flexible I-Mab already has a fairly advanced China portfolio, with…
China A selection of recent big stories from Chinese pharma, including Novo Nordisk’s updated China strategy, Chinese biotechs’ funding successes, and some significant regulatory approvals. In Q1 2020, China’s regulator the National Medical Products Administration (NMPA) approved a total of 11 new drugs, 6 imported and 5 domestic Made with Visme…
China I-Mab Biopharma CFO Jielun Zhu recaps the exciting milestones for the company over the past year since our last interview in May 2019, including most notably their NASDAQ IPO in January 2020, as well as shares some insights on the NASDAQ IPO experience. Before the IPO, we might have…
China Earlier this year, PharmaBoardroom highlighted five of the most innovative and important biotech companies making waves in the world’s second-largest pharmaceutical market, China. Here, we pick out five more firms looking to crack both the Chinese and international markets. EpimAB Biotherapeutics Founded in 2015, EpimAb Biotherapeutics is a privately owned…
China Zheru Zhang and Jielun Zhu of I-Mab Biopharma, shares their vision for the ambitious biotech company looking to develop their dual-pronged strategy of in-licensing ‘fast-to-market’ assets for their China portfolio while accelerating proof-of-concept of their internally developed candidates; what it means to operate at ‘I-Mab speed’, not just ‘China Speed’;…
See our Cookie Privacy Policy Here